PSMC2 is a Novel Prognostic Biomarker and Predicts Immunotherapeutic Responses: From Pancreatic Cancer to Pan-Cancer.
Pharmgenomics Pers Med
; 16: 747-758, 2023.
Article
de En
| MEDLINE
| ID: mdl-37581119
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Type d'étude:
Prognostic_studies
/
Risk_factors_studies
Langue:
En
Journal:
Pharmgenomics Pers Med
Année:
2023
Type de document:
Article